16-Methylen-17α-hydroxy-3,20-dioxo-pregnen-4 | 3965-17-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16-Methylen-17α-hydroxy-3,20-dioxo-pregnen-4
• 英文别名: 17α-Hydroxy-16-methylen-pregnen-(4)-dion-(3,20)；17α-Hydroxy-3,20-dioxo-16-methylen-Δ⁴-pregnen；17β-acetyl-17α-hydroxy-16-methyleneandrost-4-en-3-one；17-hydroxy-16-methylene-progesterone；16-Methylene-17alpha-hydroxyprogesterone；(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-16-methylidene-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one
• CAS: 3965-17-1
• 化学式: C₂₂H₃₀O₃
• 分子量: 342.478
• InChiKey: CAHSRYQWSFJFGS-GUCLMQHLSA-N

物化性质

• 熔点：
  208-210 °C(Solv: methanol (67-56-1))
• 沸点：
  495.2±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  16-Methylen-17α-hydroxy-3,20-dioxo-pregnen-4 在 四氯化锡 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 (1S,4aS,4bR,10aR,10bS,12aS)-1-Hydroxy-1,10a,12a-trimethyl-3-methylene-1,3,4,4a,4b,5,6,9,10,10a,10b,11,12,12a-tetradecahydro-chrysene-2,8-dione 、 (2R,4aS,4bR,10aR,10bS,12aS)-2-Hydroxy-2,10a,12a-trimethyl-3-methylene-3,4,4a,5,6,9,10,10a,10b,11,12,12a-dodecahydro-2H,4bH-chrysene-1,8-dione
  参考文献：
  名称：

  Carbon-13 nuclear magnetic resonance spectra of D-homoannulated 17-hydroxypregnan-20-ones

  摘要：

  The 13C-NMR spectra of several groups of isomeric D-homoannulated 17 alpha-hydroxypregnan-20-ones have been recorded. The chemical shifts of the various carbon atoms have been correlated with the structures of the different isomers.

  DOI：

  10.1016/0039-128x(89)90071-8
• 作为产物：
  描述：

  (8R,9S,10R,13S,14S,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-16-methylidene-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one 生成 16-Methylen-17α-hydroxy-3,20-dioxo-pregnen-4
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS<br/>[FR] PROCÉDÉ POUR ALCYNYLER DES 17-CÉTO-STÉROÏDES 16-SUBSTITUÉS
  申请人：CRYSTAL PHARMA SAU

  公开号：WO2013092668A1

  公开（公告）日：2013-06-27

  The invention relates to a process for ethynylating 16-methylene-17-keto steroids to the corresponding 16-methylene-17α-ethynyl-17β-hydroxy steroids by treatment with silyl-protected lithium acetylides followed by further desilylation. The resulting products are useful intermediates in the preparation of several pharmaceutically active agents, such as e.g. Nestorone® or melengestrol acetate.

  该发明涉及一种将16-亚甲基-17-酮类固醇乙炔化为相应的16-亚甲基-17α-乙炔基-17β-羟基类固醇的方法，方法是通过与硅保护的锂乙炔基作用，然后进行进一步的去硅化处理。所得产物是制备几种药用活性剂的有用中间体，例如Nestorone®或乙烯孕酮醋酸酯。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• 16-Methylene-17.alpha.-hydroxy-progesterones
  申请人：The Upjohn Company

  公开号：US04567001A1

  公开（公告）日：1986-01-28

  16-Methylene-17-keto steroids (III) are transformed to the corresponding 16-methylene-17.alpha.-hydroxyprogesterones (VII) which are intermediates useful in the production of betamethasone, diflorasone diacetate and melengesterol acetate.

  16-亚甲基-17-酮类固醇（III）被转化为相应的16-亚甲基-17α-羟基孕酮（VII），这些中间体在贝塔甲酸、二氟松醋酸盐和美林松醋酸盐的生产中很有用。
• Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
  申请人：AKZO N.V.

  公开号：EP0001851A1

  公开（公告）日：1979-05-16

  The invention reistse to highly concantrated liquid pharmacautical formulations of stsroids of the occtrane, and the omtrane, androstane and (19-nor) prognane series comprising tocol or a derivative thereof that is fluid se normal tomperature, or mixtures thereof, in an smount of at least 10% by weight of the formulation. and optionaly one or more of te usual suid cariers. such as vegetable oil, benzyl benzosts and/or benzyl alcohol.

  本发明涉及卵巢烷、卵烷、雄烷和(19-去甲)炔丙烷系列类固醇的高度浓缩液体药用制剂，包括在常温下具有流动性的妥尔或其衍生物，或它们的混合物，其含量至少为制剂重量的10%，还可选用一种或多种常用的添加剂，如植物油、苄基苯甲醇和/或苄醇。